New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Valeant Pharmaceuticals International's proposed $475M acquisition of Precision Dermatology. would likely be anticompetitive. Under the order, Valeant has agreed to sell Precision’s assets related to two acne treatments – Tretin-X, its branded single-agent topical tretinoin, and generic Retin-A – within 10 days of consummating the transaction. According to the FTC’s complaint, first announced in July, Valeant’s acquisition of Precision as originally proposed would likely reduce competition in the market for branded and generic single-agent topical tretinoins, and in a separate market for generic Retin-A. Reference Link
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:05 EDTVRXValeant outlook has improved, says RBC Capital
Subscribe for More Information
December 17, 2014
10:53 EDTVRXAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
December 9, 2014
09:31 EDTVRXZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use